Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.04 EUR | -0.46% | -1.84% | -10.83% |
Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Mar. 18 | Fresenius Settles With Johnson & Johnson to Market Stelara Alternative | DJ |
Sales 2024 * | 23.05B 25.04B | Sales 2025 * | 24.09B 26.17B | Capitalization | 14.17B 15.4B |
---|---|---|---|---|---|
Net income 2024 * | 1.41B 1.53B | Net income 2025 * | 1.75B 1.9B | EV / Sales 2024 * | 1.32 x |
Net Debt 2024 * | 16.32B 17.73B | Net Debt 2025 * | 15.59B 16.93B | EV / Sales 2025 * | 1.24 x |
P/E ratio 2024 * |
10.1
x | P/E ratio 2025 * |
7.9
x | Employees | 193,865 |
Yield 2024 * |
3.73% | Yield 2025 * |
4.21% | Free-Float | 73.04% |
Latest transcript on Fresenius SE & Co. KGaA
1 day | +0.10% | ||
1 week | -1.22% | ||
Current month | -2.78% | ||
1 month | -4.84% | ||
3 months | -9.30% | ||
6 months | -16.47% | ||
Current year | -10.37% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Sen
CEO | Chief Executive Officer | 55 | 21-04-11 |
Sara Hennicken
DFI | Director of Finance/CFO | 44 | 18-12-31 |
Michael Moser
CMP | Compliance Officer | - | 23-07-17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Diekmann
BRD | Director/Board Member | 69 | 15-05-19 |
Wolfgang Kirsch
CHM | Chairman | 69 | 19-12-31 |
Director/Board Member | 63 | 16-05-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.26% | 2 M€ | +13.56% | - | |
1.05% | 962 M€ | -.--% | - | |
1.01% | 79 M€ | -.--% | ||
0.92% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-19 | 25.05 | -0.44% | 296 278 |
24-03-18 | 25.16 | +0.64% | 714,052 |
24-03-15 | 25 | -0.71% | 2,247,327 |
24-03-14 | 25.18 | -1.14% | 933,882 |
24-03-13 | 25.47 | -0.12% | 1,020,514 |
Delayed Quote Xetra, March 18, 2024 at 12:35 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.37% | 15.41B | |
-11.31% | 18.18B | |
+4.50% | 12.8B | |
+1.00% | 11.37B | |
+6.42% | 10.64B | |
+3.08% | 8.13B | |
+13.89% | 7.61B | |
+8.89% | 6.87B | |
+6.98% | 6.38B | |
+6.17% | 4.75B |